BAD: Treatments that gave great hope fail against virus variants
(5 years ago)The high hope for drug treatments against Covid-19sh monochlonal antibodies are failing against coronary variants, such as those recently released in South Africa and Brazil, scientists have said. There were very high expectations for these drugs. One, produced by Regeneron in the United States, was given to Donald [...]
There were very high expectations for these drugs. One, produced by Regeneron in the United States, was given to Donald Trump and may have played an important role in his early recovery. It is being tested on hospital patients in the United Kingdom.
But to the shock of those who are working on disease therapy, all leading racers -- Regeneron, and medicines from Eli Lilly and GlaxoSmithKline -- have failed in one or more variants of Covid, Write The Guardian, translate Periscope.
Antibodies have high advantage as treatments, said Nick Cammack, who leads the Terud-19 therapeutic Axisor at the Wellcome Company. They are derived from cloning white human blood cells and imitating the effects on the immune system. They are very safe, specifically in building the target of the virus, and their use seemed very promising in the early phase of the disease.
“The challenge came at Christmas when new versions of the virus were presented in South Africa and Brazil specifically. The changes of the virus made in the climinal proteins are removing these antibodies,” he said.
So basically, most of the main anti-body therapies for Covid were lost in South Africa and Brazil variants. ”
GlacoSmythKline's treatment is still functional against these variants, but not against the one that emerged in Kent of the United Kingdom. /Periscope